(Reuters) -Strong results from AstraZeneca helped London's blue-chip index notch a record close on Thursday, while a dovish ...
The boss of AstraZeneca Plc said he does not believe the UK is the worst place to invest, striking a conciliatory tone just ...
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
FTSE 100 heavyweight AstraZeneca helped propel the blue-chip index to a record high today. Here's what investors were ...
AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback